title: [Effect of celecoxib on pulmonary hypertension of chronic hypoxia and hypercapnic rats].
abstract: OBJECTIVE
  To study the effect of celecoxib on chronic hypoxia and hypercapnic pulmonary hypertension.
  
  
  METHODS
  SD rats were randomly divided into normal control group (A), hypoxic hypercapnic group (B), hypoxic hypercapnia+ celecoxib group (C). The content of TXB2 and 6-keto-PGF1alpha in plasma and lung were detected by the technique of radioimmunology.
  
  
  RESULTS
  (1) Mean pulmonary arteria pressure(mPAP) was significantly higher in rats of B group than those of A group. mPAP was significantly higher in rats of C group than those of B group. Differences of mPAP were not significant in three groups. (2) The content of TXB2 in plasma and lung and the ratio of TXB2/6-keto-PGF1alpha were significantly higher in rats of B group than those of A group. The ratio of TXB2/6-keto-PGF1alpha was significantly higher and the content of 6-keto-PGF1alpha in plasma and lung was significantly lower in rats of C group than those of B group. (3) Light microscopy showed that WA/TA (vessel wall area/total area) and PAMT (the thickness of medial smooth cell layer) were significantly higher in rats of B group than those of A group. WA/TA and PAMT were significantly higher in rats of C group than those of B group. (4) Electron microscopy showed the thickening of vessel wall and the proliferation of collagen fiber in B group and augmentation of smooth muscle cell and abundance of myofilament in pulmonary arterioles in C group.
  
  
  CONCLUSIONS
  Celecoxib can aggravate hypoxic hypercapnia pulmonary hypertension and pulmonary vessel remodeling by increasing the ratio of TXA2/PGI2.
authors.affiliation: The First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China. zhhwz@126.com
authors.forename: Hai-Huan
authors.initials: HH
authors.lastname: Zeng
authors.forename: Ling-Jie
authors.initials: LJ
authors.lastname: Liu
authors.forename: Yu-Ping
authors.initials: YP
authors.lastname: Huang
authors.forename: Yu-Peng
authors.initials: YP
authors.lastname: Xie
authors.forename: Liang-Xing
authors.initials: LX
authors.lastname: Wang
mesh_terms: D000818:Animals; D000068579:Celecoxib; D002908:Chronic Disease; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D011464:Epoprostenol / Q000097:blood; D006935:Hypercapnia / Q000150:complications*; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000503:physiopathology*; D000860:Hypoxia / Q000150:complications*; D008297:Male; D011720:Pyrazoles / Q000009:adverse effects / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology*; D013928:Thromboxane A2 / Q000097:blood
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D013928:Thromboxane A2; D011464:Epoprostenol; D000068579:Celecoxib